Maryland Will Expand Prescription Drug Price Caps
Proposed legislation will allow the state to match Medicare pricing on 23 critical medications.
Updated on Oct. 14, 2026 in Diabetes
Live Poll
Should your state government intervene to lower prescription drug costs for residents?
Beginning in January 2027, Maryland officials plan to expand the state’s drug-pricing authority to cover 23 additional medications. This initiative aims to increase access to treatments for conditions including diabetes, heart issues, and asthma.
Why it matters
By aligning state drug costs with federal Medicare rates, the initiative seeks to directly lower out-of-pocket expenses for patients. This effort addresses ongoing concerns regarding the affordability of long-term care for chronic health conditions.
State analysis identifies 23 medications that would fall under the Prescription Drug Affordability Board's new pricing authority. Officials are currently evaluating patient savings across a broader list of 25 drugs.
The players
Wes Moore
The Governor of Maryland who plans to sign the bill into law to expand drug price regulation.
Prescription Drug Affordability Board
A state entity responsible for setting price caps on medications by matching federal Medicare rates.
The details
The policy enables the Maryland Prescription Drug Affordability Board to link state price ceilings to the maximum fair price negotiated by the federal Medicare program. The board currently uses this framework to regulate costs for drugs such as Ozempic and Jardiance. By expanding this authority, the state can regulate costs for a wider range of therapies for conditions including kidney disease and cancer.
Timeline
January 2027: The drug price bill will be introduced for the upcoming legislative session.
Health Landscape
This move mirrors the precedent established by the Inflation Reduction Act's Medicare drug-price negotiation provisions. Maryland is increasingly adopting federal pricing benchmarks to provide a state-level mechanism for managing rising pharmaceutical costs.
This policy aims to lower costs for patients managing chronic conditions like diabetes and heart disease. If you are currently paying for expensive maintenance medications, consider tracking these legislative developments and discussing your out-of-pocket costs with your doctor.
The takeaway
Maryland is preparing to expand its drug-pricing authority to improve medication affordability for residents managing chronic illness. Patients should monitor the legislative process to understand if their specific medications are among those targeted for potential price reductions.
What happens next
The legislation is scheduled for introduction during the legislative session in January 2027.
Further reading
Learn more about the latest management strategies and policy impacts in the Diabetes section.
Source note: This article includes information reported by WBAL.
Live Poll
Should your state government intervene to lower prescription drug costs for residents?
